Acutaas Chemicals
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Acutaas Chemicals is strategically pivoting towards high-margin contract development and manufacturing organization (CDMO) and specialty chemical segments, distancing itself from lower-margin commodity products. Management's bullish outlook is supported by strong demand in battery and semiconductor chemicals, with a projected 25% revenue growth for FY27. This growth is underpinned by a robust pipeline and significant investments in capacity expansion and R&D. However, the company faces execution risks related to new plant ramp-ups and geopolitical tensions affecting raw material supply. Vista's financial outlook reflects these developments, anticipating stable margins and a fair valuation aligned with intrinsic value, with an expected upside of approximately 48.75%. The industry context remains favorable, with Indian CDMOs benefiting from global supply chain shifts, although competitive pricing pressures persist. Over the next 12-24 months, key opportunities include the successful commercialization of new products and expansion into high-growth markets, while watchpoints include potential raw material supply constraints and execution risks associated with scaling operations
Why We Like This Stock
- Strong demand for battery and semiconductor chemicals supports a projected 25% revenue growth for FY27
- Strategic pivot towards high-margin CDMO and specialty chemicals enhances future profitability
- Significant investments in R&D and capacity expansion position the company for sustained growth
Things To Watch Out For
- Execution risks related to new plant ramp-ups could impact revenue realization
- Geopolitical tensions may disrupt raw material supply, affecting production stability
- Competitive pricing pressures in the industry could constrain margin expansion
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 717 | 1,007 | 1,339 | 1,506 | 1,887 |
| Profit Before Tax (Cr.) | 114 | 216 | 483 | 620 | 735 |
| PBT Margin | 15.9% | 21.4% | 3607.2% | 41.2% | 39.0% |
| Net Profit (Cr.) | 72 | 167 | 365 | 471 | 558 |
| Earnings Per Share | 8.1 | 20.1 | 44.6 | 57.5 | 68.2 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Deven Choksey | ► Accumulate | 3,567 | 29-Jul-2026 |
| HDFC Securities | ▼ Reduce | 1,358 | 30-Apr-2026 |
| IDBI Capital | ▲ Buy | 4,001 | 27-Jul-2026 |
| Kotak Securities | ▲ Buy | 2,980 | 04-May-2026 |
| Moneycontrol | ► Equalweight | nan | 06-Jul-2026 |
| Prabhudas Liladhar | ▲ Buy | 3,773 | 01-Jul-2026 |
Company Overview
Show Company Profile
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.